日照地区1068例无创性产前胎儿染色体非整倍体检测结果分析
Analysis of 1068 Pregnant Women Undergoing Non-Invasive Prenatal Testing for Fetal Chromosome Aneuploidy in Rizhao Area
DOI: 10.12677/ACM.2021.118541, PDF,   
作者: 解 萍:青岛大学附属青岛市妇女儿童医院,山东 青岛;日照市妇幼保健院,山东 日照;孙 越*:青岛大学附属青岛市妇女儿童医院,山东 青岛
关键词: 产前筛查非侵入性非整倍体唐氏综合征Prenatal Screening Non-Invasive Aneuploid Down Syndrome
摘要: 目的:评价无创产前筛查检测(non-invasive prenatal testing, NIPT)对35岁以下的孕妇进行胎儿染色体非整倍体筛查的临床价值。方法:收集2017年1月至2021年1月期间在山东日照地区产检、年龄 < 35岁,且完成了孕中期产前血清生化三联筛查(PTC)、NIPT的孕妇临床资料,共计1068例。对PTC和NIPT结果均显示高风险的孕妇进行胎儿染色体核型分析,并以核型分析结果为金标准,比较NIPT与PTC在胎儿染色体非整倍体疾病筛查的灵敏度、特异度、阳性预测率、阴性预测率。结果:1068名孕妇经血清生化三联筛查检出胎儿染色体三体高风险212例(19.85%),其中T21高风险162例(15.17%),T18高风险39例(3.65%),AFP单项MoM值异常12例(1.12%)。NIPT检出高风险36例(3.37%)。PTC及NIPT检出为高风险的孕妇行羊水穿刺术胎儿染色体核型分析,显示T21为28例,T18为6例,T13为1例。PTC检测染色体非整倍体的总体灵敏度和特异度分别是100%,82.87%,阳性预测率和阴性预测率分别为16.51%,100%。NIPT检测染色体非整倍体的总体灵敏度和特异度分别是100%,99.90%,阳性预测率和阴性预测率分别为97.22%,100%。PTC检测T21的特异度为87.12%,而NIPT检测T21的特异度为99.90%。结论:NIPT应用于 < 35岁普通孕妇的胎儿染色体非整倍体筛查具有风险低、高灵敏度、高特异度的优势,值得临床推广应用。
Abstract: Objective: To evaluate the clinical value of non-invasive prenatal testing (NIPT) for fetal chromosome aneuploidy screening in pregnant women under 35 years old. Methods: A total of 1068 cases of pregnant women with prenatal serum biochemical triple screening (PTC) and NIPT were collected from January 2017 to January 2021 in the Rizhao region of Shandong Province, age < 35 years old. The karyotype analysis was carried out as the gold standard on pregnant women, whose results of PTC and NIPT showed high-risks. Compare the sensitivity, specificity, positive prediction rate and negative prediction of NIPT and PTC screening for fetal chromosome aneuploidy. Results: 212 cases (19.85%) with a high risk of chromosome trisomy were detected in 1068 pregnant women by PTC, including 162 cases (15.17%) with high risk of T21, 39 cases (3.65%) with high risk of T18, and abnormal AFP single MoM value 12 cases (1.12%). NIPT detected 36 high-risk cases (3.37%). Karyotype analysis of pregnant women undergoing amniocentesis in high-risk cases detected by PTC or NIPT showed that T21 was in 28 cases, T18 was in 6 cases, and T13 was in 1 case. The overall sensitivity and specificity of PTC for detecting chromosomal aneuploidy are 100% and 82.87%, respectively, and the positive prediction rate and negative prediction rate are 16.51% and 100%, respectively. The overall sensitivity and specificity of NIPT for detecting chromosomal aneuploidy are 100% and 99.90%, respectively, and the positive prediction rate and negative prediction rate are 97.22% and 100%, respectively. The specificity of T21 detected by PTC is 87.12%, and the specificity of T21 detected by NIPT is 99.90%. Conclusion: NIPT technology is used to screen fetal chromosomal aneuploidy in ordinary pregnant women younger than 35 years old. NIPT has low risk, high sensitivity, high specificity and is worthy of clinical application.
文章引用:解萍, 孙越. 日照地区1068例无创性产前胎儿染色体非整倍体检测结果分析[J]. 临床医学进展, 2021, 11(8): 3691-3696. https://doi.org/10.12677/ACM.2021.118541

参考文献

[1] Johansson, L.F., De Boer, E.N., De Weerd, H.A., et al. (2017) Novel Algorithms for Improved Sensitivity in Non-Invasive Prenatal Testing. Scientific Reports, 7, Article No. 1838. [Google Scholar] [CrossRef] [PubMed]
[2] Palomaki, G.E., Kloza, E.M., Lambert-Messerlian, G.M., et al. (2011) DNA Sequencing of Maternal Plasma to Detect Down Syndrome: An International Clinical Validation Study. Genetics in Medicine, 13, 913. [Google Scholar] [CrossRef
[3] Palomaki, G.E., Cosmin Deciu, M.S., Ms, E.M.K., et al. (2012) DNA Sequencing of Maternal Plasma Reliably Identifies Trisomy 18 and Trisomy 13 as Well as Down Syndrome: An International Collaborative Study. Genetics in Medicine, 14, 296-305. [Google Scholar] [CrossRef] [PubMed]
[4] Norton, M.E., Brar, H., Weiss, J., et al. (2012) Non-Invasive Chromosomal Evaluation (NICE) Study: Results of a Multicenter Prospective Cohort Study for Detection of Fetal Trisomy 21 and Trisomy 18. American Journal of Obstetrics and Gynecology, 207, 137.e1-8. [Google Scholar] [CrossRef] [PubMed]
[5] Mccullough, R.M., Almasri, E.A., Guan, X., et al. (2014) Non-Invasive Prenatal Chromosomal Aneuploidy Testing—Clinical Experience: 100,000 Clinical Samples. PLoS ONE, 9, e109173. [Google Scholar] [CrossRef] [PubMed]
[6] 国家卫生计生委办公厅. 《国家卫生计生委办公厅关于规范有序开展孕妇外周血胎儿游离DNA产前筛查与诊断工作的通知》国卫办妇幼发(2016)45号[Z]. 2016.
[7] 赵晓曦, 武艾宁, 于荣鑫, 等. 内蒙古自治区无创产前基因检测高危孕妇的染色体异常状况分析[J]. 中华妇幼临床医学杂志(电子版), 2018, 14(2): 224-229.
[8] 杨延龙, 谢明水. 无创产前检测技术筛查染色体非整倍体疾病中的参考价值分析[J]. 中国优生与遗传杂志, 2019, 27(4): 426-428.
[9] Dai, R., Yu, Y., Zhang, H., et al. (2021) Analysis of 17,428 Pregnant Women Undergoing Non-Invasive Prenatal Testing for Fetal Chromosome in Northeast China. Medicine, 100, e24740. [Google Scholar] [CrossRef
[10] Nygren, A.O., Dean, J., Jensen, T.J., et al. (2010) Quantification of Fetal DNA by Use of Methylation-Based DNA Discrimination. Clinical Chemistry, 56, 1627-1635. [Google Scholar] [CrossRef] [PubMed]
[11] Simons, A., Shaffer, L.G. and Hastings, R.J. (2013) Cytogenetic Nomenclature: Changes in the ISCN 2013 Compared to the 2009 Edition. Cytogenetic and Genome Research, 141, 1-6. [Google Scholar] [CrossRef] [PubMed]
[12] Neyt, M., Hulstaert, F. and Gyselaers, W. (2014) Introducing the Non-Invasive Prenatal Test for Trisomy 21 in Belgium: A Cost-Consequences Analysis. BMJ Open, 4, e005922. [Google Scholar] [CrossRef] [PubMed]
[13] 孙秀敏, 张俊芳, 石彦蕊, 等. 妊娠早期母体血清miR-34a和miR-206检测联合胎儿颈项透明层厚度筛查胎儿先天性心脏病的价值[J]. 标记免疫分析与临床, 2020(3): 408-411.
[14] Verloes, A., Gillerot, Y., Van Maldergem, L., et al. (2001) Major Decrease in the Incidence of Trisomy 21 at Birth in South Belgium: Mass Impact of Triple Test? European Journal of Human Genetics, 9, 1-4. [Google Scholar] [CrossRef] [PubMed]
[15] Kostenko, E., Chantraine, F., Vandeweyer, K., et al. (2019) Clinical and Economic Impact of Adopting Noninvasive Prenatal Testing as a Primary Screening Method for Fetal Aneuploidies in the General Pregnancy Population. Fetal Diagnosis and Therapy, 45, 413-423. [Google Scholar] [CrossRef] [PubMed]
[16] 常家祯, 戚庆炜, 周希亚, 等. 10,577例基于二代测序的胎儿非整倍体异常无创产前筛查临床应用效力评估[J]. 生殖医学杂志, 27(12): 7-11.
[17] Lo, Y.M., Corbetta, N., Chamberlain, P.F., et al. (1997) Presence of Fetal DNA in Maternal Plasma and Serum. The Lancet (London, England), 350, 485-487. [Google Scholar] [CrossRef
[18] Hartwig, T.S., Ambye, L., Rensen, S., et al. (2017) Discordant Non-Invasive Prenatal Testing (NIPT)—A Systematic Review. Prenatal Diagnosis, 37, 527-539. [Google Scholar] [CrossRef] [PubMed]
[19] Fiorentino, F., Bono, S., Pizzuti, F., et al. (2016) The Importance of Determining the Limit of Detection of Non-Invasive Prenatal Testing Methods. Prenatal Diagnosis, 36, 304-311. [Google Scholar] [CrossRef] [PubMed]
[20] Gil, M.M., Accurti, V., Santacruz, B., et al. (2017) Analysis of Cell-Free DNA in Maternal Blood in Screening for Aneuploidies: Updated Meta-Analysis. Ultrasound in Obstetrics & Gynecology, 50, 302-314. [Google Scholar] [CrossRef